Searching On:

Disease:

Gene:

AKT1
ALK
APC
ATM
ATR
Beta-Catenin (CTNNB1)
BRAF
BRCA1 and BRCA2
DNA-PKcs
EGFR
ERBB2 (HER2)
ERBB3 (HER3)
ESR1
FGFR 1, 2, 3 and 4
HDM2/MDM2
HRAS
IDH1
IDH2
KIT
KRAS
MAP2K1 (MEK1)
MET
NF2
NOTCH1
NRAS
PIK3CA
PTCH (Patched)
PTEN
RET
ROS1
SMO (Smoothened)
TP53
TRK 1,2,3

ROS1

       
View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse ROS1  - General Description ROS1 is a gene that provides the code for making a protein, a receptor tyrosine kinase (RTK), that may activate several signaling pathways involved in the growth and division (proliferation), specialization (differentiation) and survival of cells. Changes in the ROS1 gene have been associated with non-small cell lung cancer (NSCLC) and a fast-growing type of central nervous system tumor, glioblastoma multiforme. These changes are due to rearrangements of the chromosome where the gene is located. Source: Genetics Home ReferenceROS1 is a receptor tyrosine kinase (RTK) that activates several signaling pathways involved in proliferation, differentiation and survival of cells. Changes in the ROS1 gene have been associated with non-small cell lung cancer (NSCLC) and glioblastoma multiforme. These changes are due to rearrangements of the chromosome where the gene is located. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
ROS1 is a gene that provides the code for making a protein, a receptor tyrosine kinase (RTK), that may activate several signaling pathways involved in the growth and division (proliferation), specialization (differentiation) and survival of cells.

Changes in the ROS1 gene have been associated with non-small cell lung cancer (NSCLC) and a fast-growing type of central nervous system tumor, glioblastoma multiforme. These changes are due to rearrangements of the chromosome where the gene is located.

Source: Genetics Home Reference
ROS1 is a receptor tyrosine kinase (RTK) that activates several signaling pathways involved in proliferation, differentiation and survival of cells.

Changes in the ROS1 gene have been associated with non-small cell lung cancer (NSCLC) and glioblastoma multiforme. These changes are due to rearrangements of the chromosome where the gene is located.

Source: Genetics Home Reference
Expand Collapse No mutation selected
The mutation of a gene provides clinicians with a very detailed look at your cancer. Knowing this information could change the course of your care. To learn how you can find out more about genetic testing please visit http://www.massgeneral.org/cancer/news/faq.aspx or contact the Cancer Center.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene
Trial Status: Showing all 7 results Per Page:
Protocol # Title Location Status Match
NCT00585195 A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer MGH Open G
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) MGH Open G
NCT02817633 A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors MGH Open G
NCT02927340 A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions MGH Open G
NCT03052608 A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC MGH Open G
NCT03093116 A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements MGH Open G
NCT03178071 Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive MGH Open G
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 7 results Per Page:

Share with your Physican

Print information for your Physician.

Print information